Keyword: Starboard Value

With a shareholder vote in favor of the BMS-Celgene marriage, the combined company will get its chance to prove it's worth the $74 billion price.

Recommendations to vote “yes” from proxy advisory firms were enough to end an activist’s efforts to scuttle the BMS-Celgene merger.

Proxy advisers will soon weigh in on BMS' $74 billion Celgene buyout, and their verdicts could sway undecided shareholders, analysts say.

Starboard Value's 197-page presentation against the BMS-Celgene deal lacks a "smoking gun," an analyst wrote. He believes the deal will go through.

Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.

What's Bristol-Myers' Plan B if its Celgene deal falls through? The company won't say whether it has one, much less what it might be.

BMS responded to Starboard Value's attempt to scuttle its $74 billion acquisition of Celgene with 46 pages laying out its reasoning for the deal.

Wellington and other large funds may oppose the BMS-Celgene merger, but the math doesn't add up for a successful thumbs-down vote, analysts report.

Starboard Value is rallying the troops against BMS' $74 billion Celgene deal, and it has more support than some expected. But will it be enough?

The Bristol-Myers rumors are true. Activist investor Starboard Value has indeed taken a stake in the company—and it’s looking to meddle further.